Centrus Energy Corp vs Tilray Brands Inc — how do they compare? Centrus Energy Corp trades at $142.02 (market cap $2.91B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Centrus Energy Corp is far larger — about 5.5× Tilray Brands Inc's market cap, and Centrus Energy Corp is more actively traded (903,777 versus 9,099,075). Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and Tilray Brands Inc for 31 Days on average.
| LEU | TLRY | |
|---|---|---|
Market Cap | $2.91B | $530.54M |
Volume | 903,777 | 9,099,075 |
Sector | Energy | Health |
52-Week High | $436.00 | $21.00 |
52-Week Low | $138.18 | $3.57 |
Typical Hold Time | 29 Days | 31 Days |
Enterprise Value | $2.22B | $684.46M |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $143.88, down 2.22% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18) but maintains profitability with 10.23% net margins. Recent news highlights Centrus' strategic position as the only US-licensed HALEU producer, benefiting from nuclear energy growth and Russian uranium import bans.
The investment case balances high growth potential in nuclear fuel supply against execution risks and premium valuation. Analyst consensus at $218.10 suggests 52% upside, but technical indicators and recent equity dilution from a $500 million offering present near-term headwinds. Success depends on contract execution and nuclear industry adoption timelines.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →